Literature DB >> 7143361

Synthesis and antitumor activity of 10-alkyl-10-deazaminopterins. A convenient synthesis of 10-deazaminopterin.

J I DeGraw, V H Brown, H Tagawa, R L Kisliuk, Y Gaumont, F M Sirotnak.   

Abstract

Requirements for large-scale synthesis of the potent antitumor drug 10-deazaminopterin have led to development of a facile synthesis of this compound and its 10-alkyl analogues. The lithium diisopropyl amide generated dianions of appropriate p-alkylbenzoic acids were alkylated with 3-methoxyallyl chloride. The resulting 4-(p-carboxyphenyl)-1-methoxy-1-butenes were brominated at pH 7-8 to afford the 2-bromo-4-(p-carboxyphenyl)butyraldehydes. Condensation with 2,4,5,6-tetraminopyrimidine and subsequent in situ oxidation of the resulting dihydropteridines yielded crystalline 10-alkyl-10-deaza-4-amino-4-deoxypteroic acids. The pteroic acids were coupled with diethyl glutamate via the mixed anhydride method, followed by saponification at room temperature, to give the target 10-deazaminopterins. The 10-alkyl compounds were approximately equipotent to 10-deazaminopterin as growth inhibitors of folate-dependent bacteria. Their abilities to inhibit Lactobacillus casei and L1210 derived dihydrofolate reductases were also similar. Transport properties in vitro were suggestive of an improved therapeutic index for the 10-alkyl analogues. Against L1210 in mice, the percent increase in life span at the LD10 dosage was +151% (methotrexate), +178% (10-deazaminopterin), +235% (10-methyl analogue), and +211% (10-ethyl analogue). 10,10-Dimethyl-10-deazaminopterin was less effective at an equimolar dosage, but the ILS at the maximum dose tested (72 mg/kg) was +135%. It was far less toxic than the other analogues possibly because of enhanced clearance.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7143361     DOI: 10.1021/jm00352a026

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy.

Authors:  J S Lee; W K Murphy; M H Shirinian; A Pang; W K Hong
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part II.

Authors:  C R Thomas; K J Stelzer; J G Douglas; W J Koh; L V Wood; R Panicker
Journal:  J Natl Med Assoc       Date:  1994-11       Impact factor: 1.798

3.  Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer.

Authors:  J S Lee; H I Libshitz; W K Murphy; D Jeffries; W K Hong
Journal:  Invest New Drugs       Date:  1990-08       Impact factor: 3.850

4.  New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties.

Authors:  F M Sirotnak; J I DeGraw; D M Moccio; L L Samuels; L J Goutas
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models.

Authors:  F M Sirotnak; J I DeGraw; F A Schmid; L J Goutas; D M Moccio
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 6.  Biological and biochemical properties of new anticancer folate antagonists.

Authors:  D W Fry; R C Jackson
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

7.  Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer.

Authors:  R L Souhami; R M Rudd; S G Spiro; R Allen; P Lamond; P G Harper
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Long-term treatment of the MRL/lpr mouse with methotrexate and 10-deazaaminopterin.

Authors:  J E Baggott; S L Morgan; L E Freeberg; B B Hudson; W H Vaughn; M Gopal Nair; C L Krumdieck; W J Koopman; R E Gay; S Gay
Journal:  Agents Actions       Date:  1992-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.